What is Zimmer Biomet Holdings, Inc.'s earnings per share (EPS)?

Zimmer Biomet Holdings, Inc. (ZBH) reported diluted earnings per share of $3.55 for fiscal year 2025. This represents a -19.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Zimmer Biomet Holdings, Inc. (ZBH) Financials

ZBH

Trailing 12 months to June 30, 2026

Revenue $8.5B +8.6% YoY

Net Income $806.7M -2.0% YoY

EPS (Diluted) $4.12 +0.5% YoY

Free Cash Flow $1.5B +3.4% YoY

Market Cap $16.8B as of Oct 3, 2026

Price / Sales 2.0x on $8.5B revenue, trailing 12 months to June 30, 2026

Price / Earnings 20.9x on $806.7M net income, trailing 12 months to June 30, 2026

Price / Book 1.3x on $12.6B equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ZBH SEC filings page.

Zimmer Biomet Holdings, Inc. (ZBH) reported $8.5B in revenue over the twelve months to Jun 30, 2026, up 8.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ZBH FY2025 2026-10-03

FY2025 growth produced more cash, but margin compression and higher leverage made each additional sales dollar less efficient.

In FY2025, operating cash flow of $1.7B exceeded net income of $705M, showing cash conversion was stronger than reported earnings alone; noncash expenses and working-capital movements materially influenced the result. Meanwhile, debt-to-equity rose from 0.4x in FY2023 to 0.5x in FY2025, meaning cash generation did not prevent a more leveraged funding structure.

Revenue grew 7.2% in FY2025, yet gross margin slipped from 71.5% to 69.7%, indicating expansion came with higher direct costs. Operating margin fell to 13.3% as selling, general, and administrative expense reached $3.3B, so overhead absorbed much of the gross-profit gain.

The current ratio improved to 2.0x even as long-term debt reached $6.9B, separating better short-term coverage from a more leveraged balance-sheet structure. Share buybacks fell to $487M from $868M, indicating a more restrained capital-return posture while financing needs increased.

Financial Health Signals

Financial Health Score 59/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Zimmer Biomet Holdings, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Zimmer Biomet Holdings, Inc. has an operating margin of 13.3%, meaning the company retains $13 of operating profit per $100 of revenue. This strong profitability earns a score of 78/100, reflecting efficient cost management and pricing power. This is down from 16.7% the prior year.

Growth

Zimmer Biomet Holdings, Inc.'s revenue grew 7.2% year-over-year to $8.2B, a solid pace of expansion. This earns a growth score of 52/100.

Leverage

Zimmer Biomet Holdings, Inc. has elevated debt relative to equity (D/E of 0.55), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 23/100, reflecting increased financial risk.

Liquidity

Zimmer Biomet Holdings, Inc.'s current ratio of 1.98 indicates adequate short-term liquidity, earning a score of 59/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Zimmer Biomet Holdings, Inc. converts 17.9% of revenue into free cash flow ($1.5B). This strong cash generation earns a score of 83/100.

Returns

Zimmer Biomet Holdings, Inc.'s ROE of 5.5% shows moderate profitability relative to equity, earning a score of 60/100. This is down from 7.2% the prior year.

Altman Z-Score Grey Zone

2.32

Zimmer Biomet Holdings, Inc. scores 2.32, placing it in the grey zone between 1.81 and 2.99. This signals moderate financial risk that warrants monitoring.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

Zimmer Biomet Holdings, Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed

2.41x

For every $1 of reported earnings, Zimmer Biomet Holdings, Inc. generates $2.41 in operating cash flow ($1.7B OCF vs $705.1M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Adequate

3.75x

Zimmer Biomet Holdings, Inc. earns $3.75 in operating income for every $1 of interest expense ($1.1B vs $292.8M). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.2B

YoY+4.8%

QoQ+4.3%

5Y CAGR+4.3%

10Y CAGR+1.2%

Zimmer Biomet Holdings, Inc. generated $2.2B in revenue in Q2 2026. This represents an increase of 4.8% from the same quarter a year earlier. Against the prior quarter it is up 4.3%.

EBITDA

$596.9M

YoY+4.4%

QoQ-7.2%

5Y CAGR+5.3%

Zimmer Biomet Holdings, Inc.'s EBITDA was $596.9M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 4.4% from the same quarter a year earlier. Against the prior quarter it is down 7.2%.

Net Income

$198.3M

YoY+29.8%

QoQ-16.7%

5Y CAGR+6.9%

Zimmer Biomet Holdings, Inc. reported $198.3M in net income in Q2 2026. This represents an increase of 29.8% from the same quarter a year earlier. Against the prior quarter it is down 16.7%.

EPS (Diluted)

$1.03

YoY+33.8%

QoQ-15.6%

5Y CAGR+9.0%

Zimmer Biomet Holdings, Inc. earned $1.03 per diluted share (EPS) in Q2 2026. This represents an increase of 33.8% from the same quarter a year earlier. Against the prior quarter it is down 15.6%.

Cash & Balance Sheet

Free Cash Flow

$393.6M

YoY+20.0%

QoQ+21.8%

5Y CAGR+1.2%

10Y CAGR+1.7%

Zimmer Biomet Holdings, Inc. generated $393.6M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 20.0% from the same quarter a year earlier. Against the prior quarter it is up 21.8%.

Cash & Debt

$410.0M

YoY-26.4%

QoQ-3.3%

5Y CAGR-17.0%

10Y CAGR-8.3%

Zimmer Biomet Holdings, Inc. held $410.0M in cash against $6.3B in long-term debt as of Q2 2026.

Dividends Per Share

$0.24

YoY0.0%

QoQ0.0%

5Y CAGR0.0%

10Y CAGR0.0%

Zimmer Biomet Holdings, Inc. paid $0.24 per share in dividends in Q2 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Shares Outstanding

191M

YoY-3.7%

QoQ-1.4%

5Y CAGR-1.8%

10Y CAGR-0.5%

Zimmer Biomet Holdings, Inc. had 191M shares outstanding in Q2 2026. This represents a decrease of 3.7% from the same quarter a year earlier. Against the prior quarter it is down 1.4%.

Margins & Returns

Gross Margin

70.8%

YoY-0.7pp

QoQ-1.6pp

5Y change-1.1pp

10Y change+10.8pp

Zimmer Biomet Holdings, Inc.'s gross margin was 70.8% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.6 percentage points.

Operating Margin

15.0%

YoY+0.5pp

QoQ-2.9pp

5Y change+2.2pp

Zimmer Biomet Holdings, Inc.'s operating margin was 15.0% in Q2 2026, reflecting core business profitability. This is up 0.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.9 percentage points.

Net Margin

9.1%

YoY+1.8pp

QoQ-2.3pp

5Y change+1.1pp

10Y change+10.7pp

Zimmer Biomet Holdings, Inc.'s net profit margin was 9.1% in Q2 2026, showing the share of revenue converted to profit. This is up 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.3 percentage points.

Return on Equity

1.6%

YoY+0.3pp

QoQ-0.3pp

5Y change+0.4pp

10Y change+1.9pp

Zimmer Biomet Holdings, Inc.'s ROE was 1.6% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 0.3 percentage points.

Capital Allocation

R&D Spending

$104.8M

YoY-7.5%

QoQ+1.4%

5Y CAGR-8.7%

Zimmer Biomet Holdings, Inc. invested $104.8M in research and development in Q2 2026. This represents a decrease of 7.5% from the same quarter a year earlier. Against the prior quarter it is up 1.4%.

Share Buybacks

$250.7M

YoY+3381.9%

QoQ+0.2%

Zimmer Biomet Holdings, Inc. spent $250.7M on share buybacks in Q2 2026, returning capital to shareholders by reducing shares outstanding. This represents an increase of 3381.9% from the same quarter a year earlier. Against the prior quarter it is up 0.2%.

Capital Expenditures

$54.2M

YoY+8.2%

QoQ+49.3%

5Y CAGR+17.1%

10Y CAGR+1.6%

Zimmer Biomet Holdings, Inc. invested $54.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 8.2% from the same quarter a year earlier. Against the prior quarter it is up 49.3%.

ZBH Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZBH quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$8.5B	$8.2B+7.2%	$7.7B+3.8%	$7.4B+6.5%	$6.9B+1.6%	$6.8B+11.4%	$6.1B-12.0%	$7.0B-12.3%	$7.9B+1.7%	$7.8B+1.8%	$7.7B+27.9%	$6.0B+28.3%	$4.7B+1.1%	$4.6B+3.4%	$4.5B+0.4%	$4.5B
Cost of Revenue	$2.6B	$2.5B+13.8%	$2.2B+5.2%	$2.1B+3.2%	$2.0B+3.0%	$2.0B+7.5%	$1.8B-6.1%	$1.9B-14.4%	$2.3B+6.5%	$2.1B-10.5%	$2.4B+32.3%	$1.8B+44.9%	$1.2B-1.9%	$1.3B+12.6%	$1.1B+0.3%	$1.1B
Gross Profit	$5.9B	$5.7B+4.6%	$5.5B+3.3%	$5.3B+7.9%	$4.9B+1.1%	$4.9B+13.1%	$4.3B-14.2%	$5.0B-11.4%	$5.7B-0.2%	$5.7B+7.3%	$5.3B+26.0%	$4.2B+22.6%	$3.4B+2.6%	$3.3B-0.3%	$3.3B+0.5%	$3.3B
R&D Expenses	$442.8M	$458.5M+4.8%	$437.4M-4.6%	$458.7M+13.0%	$406.0M-6.8%	$435.8M+35.0%	$322.8M-18.1%	$394.1M+0.6%	$391.7M+5.9%	$369.9M+1.2%	$365.6M+36.0%	$268.8M+43.4%	$187.4M-7.7%	$203.0M-10.0%	$225.6M-5.4%	$238.4M
SG&A Expenses	$3.4B	$3.3B+11.2%	$2.9B+3.2%	$2.8B+2.8%	$2.8B-2.9%	$2.8B+4.8%	$2.7B-3.5%	$2.8B-16.8%	$3.4B+8.8%	$3.1B+5.4%	$2.9B+28.9%	$2.3B+30.5%	$1.8B+0.1%	$1.7B-3.2%	$1.8B-1.5%	$1.8B
Operating Income	$1.2B	$1.1B-14.6%	$1.3B+0.6%	$1.3B+83.5%	$696.3M-19.1%	$860.3M+935.3%	$83.1M-92.5%	$1.1B+3189.9%	$33.8M-95.8%	$799.3M-2.7%	$821.1M+75.7%	$467.3M-55.0%	$1.0B-2.9%	$1.1B+2.0%	$1.0B+2.3%	$1.0B
EBITDA	N/A	$2.2B-3.9%	$2.3B+2.4%	$2.2B+37.4%	$1.6B-9.7%	$1.8B+83.2%	$981.5M-50.5%	$2.0B+84.6%	$1.1B-42.3%	$1.9B+0.1%	$1.9B+57.7%	$1.2B-16.5%	$1.4B-1.0%	$1.4B+1.2%	$1.4B+1.9%	$1.4B
Interest Expense	-$289.0M	-$292.8M-34.3%	-$218.0M-8.3%	-$201.2M-22.1%	-$164.8M+20.9%	-$208.4M+1.7%	-$212.1M+6.6%	-$227.0M+21.5%	-$289.3M-188.3%	$327.5M-8.5%	$357.9M+24.9%	$286.6M+354.2%	$63.1M-10.0%	$70.1M-3.8%	$72.9M+31.8%	$55.3M
Income Tax	$126.5M	$125.7M-4.3%	$131.4M+211.4%	$42.2M-62.4%	$112.3M+109.9%	$53.5M+155.7%	-$96.0M+59.7%	-$238.0M-320.0%	$108.2M+108.0%	-$1.3B-1519.8%	$95.0M+1257.1%	$7.0M-96.8%	$220.2M-4.1%	$229.5M-3.2%	$237.2M+8.4%	$218.9M
Net Income	$806.7M	$705.1M-22.0%	$903.8M-11.7%	$1.0B+342.5%	$231.4M-42.4%	$401.6M+389.1%	-$138.9M-112.3%	$1.1B+398.4%	-$379.2M-120.9%	$1.8B+492.9%	$305.9M+108.1%	$147.0M-79.6%	$720.3M-7.7%	$780.4M+3.4%	$755.0M-0.8%	$760.8M
EPS (Basic)	N/A	$3.56-20.0%	$4.45-9.4%	$4.91+346.4%	$1.10-43.0%	$1.93+388.1%	-$0.67-112.1%	$5.52+396.8%	-$1.86-120.7%	$8.98+486.9%	$1.53+96.2%	$0.78-81.7%	$4.26-7.4%	$4.60+6.5%	$4.32+6.7%	$4.05
EPS (Diluted)	$4.12	$3.55-19.9%	$4.43-9.2%	$4.88+343.6%	$1.10-42.4%	$1.91+385.1%	-$0.67-112.2%	$5.47+394.1%	-$1.86-120.9%	$8.90+489.4%	$1.51+96.1%	$0.77-81.7%	$4.20-7.5%	$4.54+5.8%	$4.29+6.5%	$4.03
Diluted Shares (Avg)	N/A	199M-2.6%	204M-2.8%	210M-0.3%	210M0.0%	210M+1.6%	207M+0.1%	207M+1.6%	204M-0.1%	204M+0.6%	202M+6.6%	190M+10.5%	172M-0.1%	172M-2.4%	176M-6.7%	189M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$2.2B+4.8%	$2.1B+9.3%	$2.2B+10.9%	$2.0B+9.7%	$2.1B+7.0%	$1.9B+1.1%	$2.0B+4.3%	$1.8B+4.0%
Cost of Revenue	$635.5M+7.3%	$576.2M+4.8%	$792.4M+35.1%	$559.3M+3.8%	$592.2M+7.0%	$549.8M+7.3%	$586.7M+8.9%	$538.6M+3.9%
Gross Profit	$1.5B+3.8%	$1.5B+11.1%	$1.5B+1.0%	$1.4B+12.2%	$1.5B+7.0%	$1.4B-1.3%	$1.4B+2.5%	$1.3B+4.1%
R&D Expenses	$104.8M-7.5%	$103.4M-6.5%	$118.7M+9.4%	$115.9M+3.9%	$113.3M+3.6%	$110.6M+2.5%	$108.5M-4.2%	$111.6M-4.5%
SG&A Expenses	$899.3M+10.4%	$849.9M+12.0%	$872.2M+16.8%	$811.4M+14.3%	$814.8M+10.5%	$758.8M+3.1%	$746.8M+3.4%	$709.7M+5.2%
Operating Income	$326.1M+8.7%	$373.2M+27.7%	$154.5M-60.3%	$351.3M+25.7%	$300.0M-14.6%	$292.3M+9.9%	$389.0M+9.8%	$279.5M+4.8%
EBITDA	$596.9M+4.4%	$643.2M+17.7%	$438.5M-32.8%	$634.9M+19.7%	$571.8M-3.8%	$546.7M+8.4%	$652.5M+9.6%	$530.4M+4.5%
Interest Expense	-$72.9M+8.1%	-$68.8M-3.9%	-$71.9M-16.2%	-$75.4M-38.9%	-$79.3M-55.2%	-$66.2M-30.6%	-$61.9M-23.1%	-$54.3M-6.3%
Income Tax	$55.5M-22.1%	$63.0M+35.5%	-$40.0M-181.8%	$48.0M+354.0%	$71.2M+20.5%	$46.5M+9.9%	$48.9M+136.2%	-$18.9M-133.5%
Net Income	$198.3M+29.8%	$238.1M+30.8%	$139.4M-41.8%	$230.9M-7.3%	$152.8M-37.1%	$182.0M+5.6%	$239.5M-42.9%	$249.1M+53.1%
EPS (Basic)	$1.03+33.8%	$1.22+32.6%	$0.71-40.8%	$1.17-4.9%	$0.77-34.7%	$0.92+9.5%	$1.20-40.6%	$1.23+57.7%
EPS (Diluted)	$1.03+33.8%	$1.22+34.1%	$0.71-40.3%	$1.16-5.7%	$0.77-34.7%	$0.91+8.3%	$1.19-40.5%	$1.23+59.7%
Diluted Shares (Avg)	193M-2.8%	196M-2.0%	N/A	199M-2.1%	198M-3.9%	200M-3.2%	N/A	203M-3.3%

ZBH Balance Sheet

ZBH quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$23.1B+8.1%	$21.4B-0.6%	$21.5B+2.0%	$21.1B-10.2%	$23.5B-3.9%	$24.4B-0.9%	$24.6B+2.1%	$24.1B-7.3%	$26.0B-2.5%	$26.7B-1.8%	$27.2B+181.2%	$9.7B+0.7%	$9.6B+6.5%	$9.0B+5.8%	$8.5B
Current Assets	$5.1B+9.6%	$4.7B+1.3%	$4.6B+4.1%	$4.4B-9.4%	$4.9B-3.9%	$5.1B+7.6%	$4.7B+6.7%	$4.4B-3.0%	$4.6B-2.1%	$4.7B-20.3%	$5.9B+35.7%	$4.3B+2.8%	$4.2B+13.2%	$3.7B+13.2%	$3.3B
Cash & Equivalents	$591.9M+12.6%	$525.5M+26.4%	$415.8M+10.7%	$375.7M-0.6%	$378.1M-51.2%	$774.7M+25.4%	$617.9M+13.8%	$542.8M+3.5%	$524.4M-17.3%	$634.1M-56.5%	$1.5B+34.7%	$1.1B+0.2%	$1.1B+22.2%	$884.3M+15.1%	$768.3M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$164.6M-73.1%	$612.5M-15.7%	$727.0M+8.2%	$671.6M+47.4%	$455.5M
Inventory	$2.3B+2.3%	$2.2B-6.3%	$2.4B+11.1%	$2.1B0.0%	$2.1B-1.2%	$2.2B-8.8%	$2.4B+5.7%	$2.3B+9.1%	$2.1B+5.6%	$2.0B-13.1%	$2.3B+88.9%	$1.2B+11.1%	$1.1B+8.0%	$995.3M+7.0%	$929.8M
Accounts Receivable	$1.7B+15.1%	$1.5B+2.7%	$1.4B+4.4%	$1.4B+9.7%	$1.3B-1.4%	$1.3B-6.3%	$1.4B+6.9%	$1.3B-17.4%	$1.5B-3.8%	$1.6B+10.9%	$1.4B+58.6%	$912.1M-2.6%	$936.6M+5.9%	$884.6M+5.5%	$838.8M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$9.9B+11.1%	$9.0B+1.5%	$8.8B+2.8%	$8.6B-3.8%	$8.9B-0.7%	$9.0B-2.3%	$9.2B-4.1%	$9.6B-10.1%	$10.7B+0.2%	$10.6B+7.1%	$9.9B+295.1%	$2.5B-3.7%	$2.6B+1.5%	$2.6B-2.1%	$2.6B
Total Liabilities	$10.4B+16.8%	$8.9B-1.3%	$9.0B-0.3%	$9.0B-16.2%	$10.8B-11.7%	$12.2B-0.2%	$12.2B-4.7%	$12.9B-10.0%	$14.3B-16.1%	$17.0B-1.5%	$17.3B+456.0%	$3.1B-5.3%	$3.3B+4.3%	$3.1B+4.9%	$3.0B
Current Liabilities	$2.6B+5.4%	$2.5B-14.2%	$2.9B+21.2%	$2.4B-32.0%	$3.5B+35.6%	$2.6B-25.7%	$3.4B+42.1%	$2.4B-21.1%	$3.1B+28.9%	$2.4B+47.2%	$1.6B+58.0%	$1.0B-0.7%	$1.0B+19.1%	$866.0M-0.1%	$867.1M
Non-Current Liabilities	$7.8B+21.2%	$6.4B+4.7%	$6.2B-7.9%	$6.7B-8.8%	$7.3B-24.2%	$9.7B+9.7%	$8.8B-15.6%	$10.4B-7.0%	$11.2B-23.4%	$14.6B-6.5%	$15.7B+651.7%	$2.1B-7.4%	$2.2B-1.4%	$2.3B+6.9%	$2.1B
Long-Term Debt	$6.9B+29.8%	$5.3B+9.7%	$4.9B-5.5%	$5.2B-5.7%	$5.5B-28.4%	$7.6B+13.5%	$6.7B-20.1%	$8.4B-5.6%	$8.9B-16.4%	$10.7B-7.2%	$11.5B+706.6%	$1.4B-14.8%	$1.7B-2.8%	$1.7B+9.2%	$1.6B
Total Equity	$12.7B+1.8%	$12.5B-0.1%	$12.5B+3.8%	$12.0B-5.1%	$12.7B+3.8%	$12.2B-1.6%	$12.4B+9.9%	$11.3B-4.0%	$11.7B+21.4%	$9.7B-2.2%	$9.9B+51.0%	$6.5B+4.0%	$6.3B+7.4%	$5.9B+6.4%	$5.5B
Retained Earnings	$11.6B+4.6%	$11.1B+6.8%	$10.4B+8.6%	$9.6B-7.1%	$10.3B+2.0%	$10.1B-3.3%	$10.4B+9.9%	$9.5B-5.3%	$10.0B+18.4%	$8.5B+1.4%	$8.3B-0.2%	$8.4B+8.4%	$7.7B+8.8%	$7.1B+10.3%	$6.4B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$22.8B-0.3%	$22.7B+2.4%	$23.1B+8.1%	$23.5B+8.1%	$22.9B+6.3%	$22.2B+3.4%	$21.4B-0.6%	$21.7B+2.4%
Current Assets	$5.1B+0.8%	$5.0B-11.2%	$5.1B+9.6%	$5.8B+20.0%	$5.1B+8.9%	$5.6B+20.7%	$4.7B+1.3%	$4.9B+11.3%
Cash & Equivalents	$410.0M-26.4%	$424.2M-69.4%	$591.9M+12.6%	$1.3B+127.2%	$556.9M+32.6%	$1.4B+252.3%	$525.5M+26.4%	$569.0M+94.8%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$2.3B-7.5%	$2.2B+0.1%	$2.3B+2.3%	$2.5B+4.9%	$2.5B+3.6%	$2.2B-6.0%	$2.2B-6.3%	$2.4B+2.0%
Accounts Receivable	$1.8B+9.8%	$1.7B+12.7%	$1.7B+15.1%	$1.6B+7.9%	$1.6B+13.6%	$1.5B+6.0%	$1.5B+2.7%	$1.5B+10.5%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$9.9B+2.2%	$9.9B+10.5%	$9.9B+11.1%	$9.7B+8.9%	$9.7B+10.0%	$9.0B+2.2%	$9.0B+1.5%	$8.9B+2.3%
Total Liabilities	$10.2B-1.6%	$10.0B+2.7%	$10.4B+16.8%	$10.7B+14.8%	$10.3B+17.8%	$9.8B+10.6%	$8.9B-1.3%	$9.3B+7.3%
Current Liabilities	$3.0B+11.6%	$2.9B+24.8%	$2.6B+5.4%	$2.4B-32.7%	$2.7B-25.2%	$2.3B-18.0%	$2.5B-14.2%	$3.6B+72.4%
Non-Current Liabilities	$7.2B-6.3%	$7.2B-4.1%	$7.8B+21.2%	$8.3B+44.3%	$7.6B+47.8%	$7.5B+23.7%	$6.4B+4.7%	$5.8B-13.0%
Long-Term Debt	$6.3B-7.0%	$6.3B-4.3%	$6.9B+29.8%	$7.5B+58.6%	$6.8B+70.7%	$6.6B+36.3%	$5.3B+9.7%	$4.7B-7.6%
Total Equity	$12.6B+0.8%	$12.7B+2.2%	$12.7B+1.8%	$12.8B+3.1%	$12.5B-1.7%	$12.4B-1.6%	$12.5B-0.1%	$12.4B-1.1%
Retained Earnings	$12.0B+5.5%	$11.8B+5.1%	$11.6B+4.6%	$11.5B+5.6%	$11.3B+5.9%	$11.2B+6.9%	$11.1B+6.8%	$10.9B+8.9%

ZBH Cash Flow Statement

ZBH quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	$1.7B	$1.7B+13.2%	$1.5B-5.2%	$1.6B+16.6%	$1.4B-9.5%	$1.5B+24.5%	$1.2B-24.0%	$1.6B-9.2%	$1.7B+10.4%	$1.6B-3.1%	$1.6B+92.1%	$849.8M-19.9%	$1.1B+10.1%	$963.1M-16.4%	$1.2B-2.1%	$1.2B
Depreciation & Amortization	N/A	$1.1B+9.8%	$996.3M+4.7%	$951.7M+2.7%	$926.4M-1.2%	$937.7M+4.4%	$898.4M+3.1%	$871.0M-16.3%	$1.0B-2.1%	$1.1B+2.3%	$1.0B+45.9%	$712.4M+89.6%	$375.8M+4.8%	$358.5M-1.3%	$363.1M+0.9%	$359.9M
Stock-Based Compensation	N/A	$90.2M-10.7%	$101.0M+1.2%	$99.8M-5.0%	$105.0M+38.2%	$76.0M+3.0%	$73.8M-4.4%	$77.2M+17.9%	$65.5M+22.0%	$53.7M-6.3%	$57.3M+23.5%	$46.4M-6.1%	$49.4M+1.9%	$48.5M-11.8%	$55.0M-9.1%	$60.5M
Capital Expenditures	$220.3M	$224.5M+10.2%	$203.8M-30.0%	$291.1M+54.9%	$187.9M+30.8%	$143.6M+28.3%	$111.9M-43.6%	$198.4M+21.9%	$162.7M+4.3%	$156.0M-15.5%	$184.7M+10.1%	$167.7M+15.7%	$144.9M+44.9%	$100.0M-12.8%	$114.7M+0.8%	$113.8M
Free Cash Flow	$1.5B	$1.5B+13.7%	$1.3B+0.4%	$1.3B+10.5%	$1.2B-13.8%	$1.4B+24.1%	$1.1B-21.2%	$1.4B-12.5%	$1.6B+11.1%	$1.4B-1.5%	$1.4B+112.2%	$682.1M-25.5%	$915.6M+6.1%	$863.1M-16.8%	$1.0B-2.4%	$1.1B
Investing Cash Flow	-$835.1M	-$2.0B-122.5%	-$888.1M-14.0%	-$778.9M	N/A	-$503.6M+18.0%	-$613.8M+15.8%	-$729.3M-75.1%	-$416.6M+18.4%	-$510.8M+69.8%	-$1.7B	N/A	N/A	-$282.5M+52.3%	-$592.1M+5.2%	-$624.4M
Financing Cash Flow	-$1.1B	$326.0M+167.3%	-$484.5M+36.5%	-$763.5M	N/A	-$1.3B-209.6%	-$421.8M+45.9%	-$779.9M+40.1%	-$1.3B-7.6%	-$1.2B-62.9%	-$743.2M	N/A	N/A	-$467.3M-7.1%	-$436.5M+4.2%	-$455.8M
Dividends Paid	$188.4M	$190.3M-2.9%	$196.0M-2.4%	$200.9M-0.1%	$201.2M+0.5%	$200.1M+0.8%	$198.5M+0.9%	$196.7M+0.8%	$195.2M+0.8%	$193.6M+2.8%	$188.4M+19.9%	$157.1M+8.0%	$145.5M+9.9%	$132.4M+40.3%	$94.4M	N/A
Share Buybacks	$750.8M	$487.0M-43.9%	$868.0M+25.4%	$692.2M+447.6%	$126.4M	N/A	N/A	N/A	N/A	N/A	$415.5M+177.0%	$150.0M-62.6%	$400.9M-44.4%	$720.8M+48.4%	$485.6M-53.8%	$1.1B

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$447.8M+18.4%	$359.4M-6.1%	$517.4M+2.2%	$418.7M+5.8%	$378.2M+2.4%	$382.8M+67.9%	$506.3M-14.0%	$395.7M+17.2%
Depreciation & Amortization	$270.8M-0.4%	$270.0M+6.1%	$284.0M+7.7%	$283.6M+13.0%	$271.8M+11.7%	$254.4M+6.6%	$263.6M+9.3%	$250.9M+4.0%
Stock-Based Compensation	N/A	$24.2M+23.5%	N/A	N/A	N/A	$19.6M-32.4%	N/A	N/A
Capital Expenditures	$54.2M+8.2%	$36.3M-18.6%	$74.8M+45.2%	$55.0M+23.6%	$50.1M-4.9%	$44.6M-19.1%	$51.5M-18.0%	$44.5M-47.2%
Free Cash Flow	$393.6M+20.0%	$323.1M-4.5%	$442.6M-2.7%	$363.7M+3.6%	$328.1M+3.6%	$338.2M+95.6%	$454.8M-13.5%	$351.2M+38.6%
Investing Cash Flow	-$190.8M+86.2%	-$159.0M-50.0%	-$322.0M-10.6%	-$163.3M-5.4%	-$1.4B-460.5%	-$106.0M+45.6%	-$291.2M-31.9%	-$154.9M+6.5%
Financing Cash Flow	-$271.1M-265.5%	-$369.2M-164.2%	-$897.0M-272.8%	$483.8M+574.8%	$163.8M+278.2%	$575.4M+1248.5%	-$240.6M+4.3%	-$101.9M+48.0%
Dividends Paid	$46.5M-2.1%	$46.9M-1.9%	$47.5M-1.0%	$47.5M-3.5%	$47.5M-3.8%	$47.8M-3.2%	$48.0M-4.4%	$49.2M-1.8%
Share Buybacks	$250.7M+3381.9%	$250.1M+8.8%	$250.0M+246.3%	$0-100.0%	$7.2M-91.6%	$229.8M+102.3%	$72.2M-82.4%	$596.3M

ZBH Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ZBH quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	69.7%-1.7pp	71.5%-0.4pp	71.8%+0.9pp	70.9%-0.4pp	71.3%+1.1pp	70.2%-1.8pp	72.1%+0.7pp	71.4%-1.3pp	72.7%+3.7pp	68.9%-1.0pp	70.0%-3.3pp	73.3%+1.1pp	72.2%-2.7pp	74.8%0.0pp	74.8%
Operating Margin	13.3%-3.4pp	16.7%-0.5pp	17.3%+7.3pp	10.0%-2.6pp	12.6%+11.2pp	1.4%-14.6pp	16.0%+15.6pp	0.4%-9.8pp	10.2%-0.5pp	10.7%+2.9pp	7.8%-14.4pp	22.2%-0.9pp	23.1%-0.3pp	23.4%+0.4pp	23.0%
Net Margin	8.6%-3.2pp	11.8%-2.1pp	13.9%+10.5pp	3.3%-2.5pp	5.9%+8.2pp	-2.3%-18.5pp	16.3%+21.0pp	-4.8%-28.0pp	23.2%+19.3pp	4.0%+1.5pp	2.5%-13.0pp	15.4%-1.5pp	16.9%0.0pp	16.9%-0.2pp	17.1%
Return on Equity	5.5%-1.7pp	7.2%-1.0pp	8.2%+6.3pp	1.9%-1.2pp	3.2%+4.3pp	-1.1%-10.3pp	9.1%+12.5pp	-3.4%-18.8pp	15.5%+12.3pp	3.2%+1.7pp	1.5%-9.5pp	11.0%-1.4pp	12.4%-0.5pp	12.9%-0.9pp	13.8%
Return on Assets	3.0%-1.2pp	4.2%-0.5pp	4.8%+3.7pp	1.1%-0.6pp	1.7%+2.3pp	-0.6%-5.2pp	4.6%+6.2pp	-1.6%-8.5pp	7.0%+5.8pp	1.1%+0.6pp	0.5%-6.9pp	7.5%-0.7pp	8.1%-0.3pp	8.4%-0.6pp	8.9%
Current Ratio	1.98+0.1x	1.91+0.3x	1.61-0.3x	1.88+0.5x	1.41-0.6x	1.99+0.6x	1.37-0.5x	1.83+0.3x	1.49-0.5x	1.96-1.7x	3.62-0.6x	4.21+0.1x	4.07-0.2x	4.28+0.5x	3.78
Debt-to-Equity	0.55+0.1x	0.430.0x	0.390.0x	0.430.0x	0.43-0.2x	0.63+0.1x	0.54-0.2x	0.750.0x	0.76-0.3x	1.10-0.1x	1.16+0.9x	0.220.0x	0.270.0x	0.290.0x	0.29
Asset Turnover	0.360.0x	0.360.0x	0.340.0x	0.330.0x	0.290.0x	0.250.0x	0.280.0x	0.330.0x	0.300.0x	0.29+0.1x	0.22-0.3x	0.480.0x	0.480.0x	0.500.0x	0.52
FCF Margin	17.9%+1.0pp	16.9%-0.6pp	17.4%+0.6pp	16.8%-3.0pp	19.9%+2.0pp	17.8%-2.1pp	19.9%-0.1pp	20.0%+1.7pp	18.3%-0.6pp	18.9%+7.5pp	11.4%-8.2pp	19.6%+0.9pp	18.7%-4.5pp	23.2%-0.7pp	23.9%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	70.8%-0.7pp	72.4%+1.2pp	64.7%-6.3pp	72.0%+1.6pp	71.5%0.0pp	71.2%-1.7pp	71.0%-1.2pp	70.5%0.0pp
Operating Margin	15.0%+0.5pp	17.9%+2.6pp	6.9%-12.3pp	17.5%+2.2pp	14.4%-3.7pp	15.3%+1.2pp	19.2%+1.0pp	15.3%+0.1pp
Net Margin	9.1%+1.8pp	11.4%+1.9pp	6.2%-5.6pp	11.5%-2.1pp	7.4%-5.1pp	9.5%+0.4pp	11.8%-9.8pp	13.7%+4.4pp
Return on Equity	1.6%+0.3pp	1.9%+0.4pp	1.1%-0.8pp	1.8%-0.2pp	1.2%-0.7pp	1.5%+0.1pp	1.9%-1.4pp	2.0%+0.7pp
Return on Assets	0.9%+0.2pp	1.1%+0.2pp	0.6%-0.5pp	1.0%-0.2pp	0.7%-0.5pp	0.8%0.0pp	1.1%-0.8pp	1.1%+0.4pp
Current Ratio	1.69-0.2x	1.73-0.7x	1.98+0.1x	2.43+1.1x	1.87+0.6x	2.44+0.8x	1.91+0.3x	1.36-0.7x
Debt-to-Equity	0.500.0x	0.500.0x	0.55+0.1x	0.59+0.2x	0.54+0.2x	0.53+0.1x	0.430.0x	0.380.0x
Asset Turnover	0.100.0x	0.090.0x	0.100.0x	0.090.0x	0.090.0x	0.090.0x	0.090.0x	0.080.0x
FCF Margin	18.1%+2.3pp	15.5%-2.2pp	19.7%-2.7pp	18.2%-1.1pp	15.8%-0.5pp	17.7%+8.6pp	22.5%-4.6pp	19.3%+4.8pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Zimmer Biomet Holdings, Inc. ZBH	FY2025	$8.2B	$705.1M	8.6%	$16.8B	59/100
Smith & Nephew plc SNN	FY2025	$6.2B	$625.0M	10.1%	$11.1B	35/100
STERIS plc STE	FY2026	$5.9B	$782.3M	13.2%	$20.3B	66/100
Insulet Corporation PODD	FY2025	$2.7B	$247.1M	9.1%	$9.1B	75/100
DexCom, Inc. DXCM	FY2025	$4.7B	$836.3M	17.9%	$32.2B	69/100

Where Zimmer Biomet Holdings, Inc. Ranks

Frequently Asked Questions

What is Zimmer Biomet Holdings, Inc.'s annual revenue?

Zimmer Biomet Holdings, Inc. (ZBH) reported $8.2B in total revenue for fiscal year 2025. This represents a 7.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Zimmer Biomet Holdings, Inc.'s revenue growing?

Zimmer Biomet Holdings, Inc. (ZBH) revenue grew by 7.2% year-over-year, from $7.7B to $8.2B in fiscal year 2025.

Is Zimmer Biomet Holdings, Inc. profitable?

Yes, Zimmer Biomet Holdings, Inc. (ZBH) reported a net income of $705.1M in fiscal year 2025, with a net profit margin of 8.6%.

What is Zimmer Biomet Holdings, Inc.'s EBITDA?

Zimmer Biomet Holdings, Inc. (ZBH) had EBITDA of $2.2B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Zimmer Biomet Holdings, Inc. have?

As of fiscal year 2025, Zimmer Biomet Holdings, Inc. (ZBH) had $591.9M in cash and equivalents against $6.9B in long-term debt.

What is Zimmer Biomet Holdings, Inc.'s gross margin?

Zimmer Biomet Holdings, Inc. (ZBH) had a gross margin of 69.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Zimmer Biomet Holdings, Inc.'s operating margin?

Zimmer Biomet Holdings, Inc. (ZBH) had an operating margin of 13.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Zimmer Biomet Holdings, Inc.'s net profit margin?

Zimmer Biomet Holdings, Inc. (ZBH) had a net profit margin of 8.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Does Zimmer Biomet Holdings, Inc. pay dividends?

Yes, Zimmer Biomet Holdings, Inc. (ZBH) paid $0.96 per share in dividends during fiscal year 2025.

What is Zimmer Biomet Holdings, Inc.'s return on equity (ROE)?

Zimmer Biomet Holdings, Inc. (ZBH) has a return on equity of 5.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Zimmer Biomet Holdings, Inc.'s free cash flow?

Zimmer Biomet Holdings, Inc. (ZBH) generated $1.5B in free cash flow during fiscal year 2025. This represents a 13.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Zimmer Biomet Holdings, Inc.'s operating cash flow?

Zimmer Biomet Holdings, Inc. (ZBH) generated $1.7B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Zimmer Biomet Holdings, Inc.'s total assets?

Zimmer Biomet Holdings, Inc. (ZBH) had $23.1B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Zimmer Biomet Holdings, Inc.'s capital expenditures?

Zimmer Biomet Holdings, Inc. (ZBH) invested $224.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Zimmer Biomet Holdings, Inc. spend on research and development?

Zimmer Biomet Holdings, Inc. (ZBH) invested $458.5M in research and development during fiscal year 2025.

Does Zimmer Biomet Holdings, Inc. buy back shares?

Yes, Zimmer Biomet Holdings, Inc. (ZBH) spent $487.0M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Zimmer Biomet Holdings, Inc. have outstanding?

Zimmer Biomet Holdings, Inc. (ZBH) had 196M shares outstanding as of fiscal year 2025.

What is Zimmer Biomet Holdings, Inc.'s current ratio?

Zimmer Biomet Holdings, Inc. (ZBH) had a current ratio of 1.98 as of fiscal year 2025, which is generally considered healthy.

What is Zimmer Biomet Holdings, Inc.'s debt-to-equity ratio?

Zimmer Biomet Holdings, Inc. (ZBH) had a debt-to-equity ratio of 0.55 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Zimmer Biomet Holdings, Inc.'s return on assets (ROA)?

Zimmer Biomet Holdings, Inc. (ZBH) had a return on assets of 3.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Zimmer Biomet Holdings, Inc.'s P/E ratio?

Zimmer Biomet Holdings, Inc. (ZBH) trades at 20.9x earnings, its market capitalization divided by net income of $806.7M net income, trailing 12 months to June 30, 2026. The market capitalization is $16.8B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Zimmer Biomet Holdings, Inc.'s price-to-sales ratio?

Zimmer Biomet Holdings, Inc. (ZBH) trades at 2.0x sales, its market capitalization divided by revenue of $8.5B revenue, trailing 12 months to June 30, 2026. The market capitalization is $16.8B as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Zimmer Biomet Holdings, Inc.'s Altman Z-Score?

Zimmer Biomet Holdings, Inc. (ZBH) has an Altman Z-Score of 2.32, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Zimmer Biomet Holdings, Inc.'s Piotroski F-Score?

Zimmer Biomet Holdings, Inc. (ZBH) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Zimmer Biomet Holdings, Inc.'s earnings high quality?

Zimmer Biomet Holdings, Inc. (ZBH) has an earnings quality ratio of 2.41x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Zimmer Biomet Holdings, Inc. cover its interest payments?

Zimmer Biomet Holdings, Inc. (ZBH) has an interest coverage ratio of 3.75x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Zimmer Biomet Holdings, Inc.?

Zimmer Biomet Holdings, Inc. (ZBH) scores 59 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.